Search

Your search keyword '"Lewis, Jason S"' showing total 426 results
Start Over Author "Lewis, Jason S" Publication Year Range Last 3 years
426 results on '"Lewis, Jason S"'

3. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer

Author

Bojmar, Linda, Zambirinis, Constantinos P., Hernandez, Jonathan M., Chakraborty, Jayasree, Shaashua, Lee, Kim, Junbum, Johnson, Kofi Ennu, Hanna, Samer, Askan, Gokce, Burman, Jonas, Ravichandran, Hiranmayi, Zheng, Jian, Jolissaint, Joshua S., Srouji, Rami, Song, Yi, Choubey, Ankur, Kim, Han Sang, Cioffi, Michele, van Beek, Elke, Sigel, Carlie, Jessurun, Jose, Velasco Riestra, Paulina, Blomstrand, Hakon, Jönsson, Carolin, Jönsson, Anette, Lauritzen, Pernille, Buehring, Weston, Ararso, Yonathan, Hernandez, Dylanne, Vinagolu-Baur, Jessica P., Friedman, Madison, Glidden, Caroline, Firmenich, Laetitia, Lieberman, Grace, Mejia, Dianna L., Nasar, Naaz, Mutvei, Anders P., Paul, Doru M., Bram, Yaron, Costa-Silva, Bruno, Basturk, Olca, Boudreau, Nancy, Zhang, Haiying, Matei, Irina R., Hoshino, Ayuko, Kelsen, David, Sagi, Irit, Scherz, Avigdor, Scherz-Shouval, Ruth, Yarden, Yosef, Oren, Moshe, Egeblad, Mikala, Lewis, Jason S., Keshari, Kayvan, Grandgenett, Paul M., Hollingsworth, Michael A., Rajasekhar, Vinagolu K., Healey, John H., Björnsson, Bergthor, Simeone, Diane M., Tuveson, David A., Iacobuzio-Donahue, Christine A., Bromberg, Jaqueline, Vincent, C. Theresa, O’Reilly, Eileen M., DeMatteo, Ronald P., Balachandran, Vinod P., D’Angelica, Michael I., Kingham, T. Peter, Allen, Peter J., Simpson, Amber L., Elemento, Olivier, Sandström, Per, Schwartz, Robert E., Jarnagin, William R., and Lyden, David

Published
2024
Full Text
View/download PDF

6. Radiotherapy and theranostics: a Lancet Oncology Commission

Author

Abdel-Wahab, May, Giammarile, Francesco, Carrara, Mauro, Paez, Diana, Hricak, Hedvig, Ayati, Nayyereh, Li, Jing Jing, Mueller, Malina, Aggarwal, Ajay, Al-Ibraheem, Akram, Alkhatib, Sondos, Atun, Rifat, Bello, Abubakar, Berger, Daniel, Delgado Bolton, Roberto C, Buatti, John M, Burt, Graeme, Bjelac, Olivera Ciraj, Cordero-Mendez, Lisbeth, Dosanjh, Manjit, Eichler, Thomas, Fidarova, Elena, Gondhowiardjo, Soehartati, Gospodarowicz, Mary, Grover, Surbhi, Hande, Varsha, Harsdorf-Enderndorf, Ekaterina, Herrmann, Ken, Hofman, Michael S, Holmberg, Ola, Jaffray, David, Knoll, Peter, Kunikowska, Jolanta, Lewis, Jason S, Lievens, Yolande, Mikhail-Lette, Miriam, Ostwald, Dennis, Palta, Jatinder R, Peristeris, Platon, Rosa, Arthur A, Salem, Soha Ahmed, dos Santos, Marcos A, Sathekge, Mike M, Shrivastava, Shyam Kishore, Titovich, Egor, Urbain, Jean-Luc, Vanderpuye, Verna, Wahl, Richard L, Yu, Jennifer S, Zaghloul, Mohamed Saad, Zhu, Hongcheng, and Scott, Andrew M

Published
2024
Full Text
View/download PDF

8. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial

Author

Tendler, Salomon, Dunphy, Mark P, Agee, Matthew, O'Donoghue, Joseph, Aly, Rania G, Choudhury, Noura J, Kesner, Adam, Kirov, Assen, Mauguen, Audrey, Baine, Marina K, Schoder, Heiko, Weber, Wolfgang A, Rekhtman, Natasha, Lyashchenko, Serge K, Bodei, Lisa, Morris, Michael J, Lewis, Jason S, Rudin, Charles M, and Poirier, John T

Published
2024
Full Text
View/download PDF

10. Dietary intake and glutamine-serine metabolism control pathologic vascular stiffness

Author

Rachedi, Nesrine S., Tang, Ying, Tai, Yi-Yin, Zhao, Jingsi, Chauvet, Caroline, Grynblat, Julien, Akoumia, Kouamé Kan Firmin, Estephan, Leonard, Torrino, Stéphanie, Sbai, Chaima, Ait-Mouffok, Amel, Latoche, Joseph D., Al Aaraj, Yassmin, Brau, Frederic, Abélanet, Sophie, Clavel, Stephan, Zhang, Yingze, Guillermier, Christelle, Kumar, Naveen V.G., Tavakoli, Sina, Mercier, Olaf, Risbano, Michael G., Yao, Zhong-Ke, Yang, Guangli, Ouerfelli, Ouathek, Lewis, Jason S., Montani, David, Humbert, Marc, Steinhauser, Matthew L., Anderson, Carolyn J., Oldham, William M., Perros, Frédéric, Bertero, Thomas, and Chan, Stephen Y.

Published
2024
Full Text
View/download PDF

11. Production and regulatory issues for theranostics

Author

Giammarile, Francesco, Paez, Diana, Zimmermann, Richard, Cutler, Cathy S, Jalilian, Amirreza, Korde, Aruna, Knoll, Peter, Ayati, Nayyereh, Lewis, Jason S, Lapi, Suzanne E, Delgado Bolton, Roberto C, Kunikowska, Jolanta, Estrada Lobato, Enrique, Urbain, Jean-Luc, Holmberg, Ola, Abdel-Wahab, May, and Scott, Andrew M

Published
2024
Full Text
View/download PDF

13. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics

Author

Scott, Andrew M, Zeglis, Brian M, Lapi, Suzanne E, Scott, Peter J H, Windhorst, Albert D, Abdel-Wahab, May, Giammarile, Francesco, Paez, Diana, Jalilian, Amirreza, Knoll, Peter, Korde, Aruna, Vichare, Shrikant, Ayati, Nayyereh, Lee, Sze Ting, Lyashchenko, Serge K, Zhang, Jingjing, Urbain, Jean Luc, and Lewis, Jason S

Published
2024
Full Text
View/download PDF

15. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer

Author

Bakht, Martin K., Yamada, Yasutaka, Ku, Sheng-Yu, Venkadakrishnan, Varadha Balaji, Korsen, Joshua A., Kalidindi, Teja M., Mizuno, Kei, Ahn, Shin Hye, Seo, Ji-Heui, Garcia, Maria Mica, Khani, Francesca, Elemento, Olivier, Long, Henry W., Chaglassian, Alain, Pillarsetty, Nagavarakishore, Lewis, Jason S., Freedman, Matthew, Belanger, Anthony P., Nguyen, Quang-De, and Beltran, Himisha

Published
2023
Full Text
View/download PDF

17. Novel Positron-Emitting Radiopharmaceuticals

Author

Keinänen, Outi, Nash, Aaron G., Sarrett, Samantha M., Sarparanta, Mirkka, Lewis, Jason S., Zeglis, Brian M., Volterrani, Duccio, editor, Erba, Paola A., editor, Strauss, H. William, editor, Mariani, Giuliano, editor, and Larson, Steven M., editor

Published
2022
Full Text
View/download PDF

20. 89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia.

Author

Herrero Alvarez, Natalia, Molvi, Zaki, Lupo, Kyle, Urraca, Jessica, Balderes, Paul, Nyakatura, Elisabeth K., Khan, Abdul G., Viray, Tara, Lewis, Jason S., and O'Reilly, Richard J.

Subjects
ACUTE myeloid leukemia, HEMATOPOIETIC stem cell transplantation, CHIMERIC proteins, KILLER cells, LEUKEMIA, T cells
Abstract

Purpose: Immune cells are capable of eliminating leukemic cells, as evidenced by outcomes in hematopoietic cell transplantation (HCT). However, patients who fail induction therapy will not benefit from HCT due to their minimal residual disease (MRD) status. Thus, we aimed to develop an immunomodulatory agent to reduce MRD by activating immune effector cells in the presence of leukaemia cells via a novel fusion protein that chimerises two clinically tolerated biologics: a CD33 antibody and the IL15Ra/IL15 complex (CD33xIL15). Methods: We generated a set of CD33xIL15 fusion protein constructs with varying configurations and identified those with the best in vitro AML-binding, T cell activation, and NK cell potentiation. Using 89Zr-immunoPET imaging we then evaluated the biodistribution and in vivo tumour retention of the most favourable CD33xIL15 constructs in an AML xenograft model. Ex vivo biodistribution studies were used to confirm the pharmacokinetics of the constructs. Results: Two of the generated fusion proteins, CD33xIL15 (N72D) and CD33xIL15wt, demonstrated optimal in vitro behaviour and were further evaluated in vivo. These studies revealed that the CD33xIL15wt candidate was capable of being retained in the tumour for as long as its parental CD33 antibody, Lintuzumab (13.9 ± 3.1%ID/g vs 18.6 ± 1.1%ID/g at 120 h). Conclusion: This work demonstrates that CD33xIL15 fusion proteins are capable of targeting leukemic cells and stimulating local T cells in vitro and of concentrating in the tumour in AML xenografts. It also highlights the importance of 89Zr-immunoPET to guide the development and selection of tumour-targeted antibody-cytokine fusion proteins. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac.

Author

Bauer, David, De Gregorio, Roberto, Pratt, Edwin C., Bell, Abram, Michel, Alexa, and Lewis, Jason S.

Subjects
PROSTATE-specific membrane antigen, POSITRON emission tomography, TUMOR microenvironment, GENETIC translation, IN vivo studies, RADIOACTIVE tracers
Abstract

Purpose: The radionuclide pair cerium-134/lanthanum-134 (134Ce/134La) was recently proposed as a suitable diagnostic counterpart for the therapeutic alpha-emitter actinium-225 (225Ac). The unique properties of 134Ce offer perspectives for developing innovative in vivo investigations that are not possible with 225Ac. In this work, 225Ac- and 134Ce-labelled tracers were directly compared using internalizing and slow-internalizing cancer models to evaluate their in vivo comparability, progeny meandering, and potential as a matched theranostic pair for clinical translation. Despite being an excellent chemical match, 134Ce/134La has limitations to the setting of quantitative positron emission tomography imaging. Methods: The precursor PSMA-617 and a macropa-based tetrazine-conjugate (mcp-PEG8-Tz) were radiolabelled with 225Ac or 134Ce and compared in vitro and in vivo using standard (radio)chemical methods. Employing biodistribution studies and positron emission tomography (PET) imaging in athymic nude mice, the radiolabelled PSMA-617 tracers were evaluated in a PC3/PIP (PC3 engineered to express a high level of prostate-specific membrane antigen) prostate cancer mouse model. The 225Ac and 134Ce-labelled mcp-PEG8-Tz were investigated in a BxPC-3 pancreatic tumour model harnessing the pretargeting strategy based on a trans-cyclooctene-modified 5B1 monoclonal antibody. Results: In vitro and in vivo studies with both 225Ac and 134Ce-labelled tracers led to comparable results, confirming the matching pharmacokinetics of this theranostic pair. However, PET imaging of the 134Ce-labelled precursors indicated that quantification is highly dependent on tracer internalization due to the redistribution of 134Ce's PET-compatible daughter 134La. Consequently, radiotracers based on internalizing vectors like PSMA-617 are suited for this theranostic pair, while slow-internalizing 225Ac-labelled tracers are not quantitatively represented by 134Ce PET imaging. Conclusion: When employing slow-internalizing vectors, 134Ce might not be an ideal match for 225Ac due to the underestimation of tumour uptake caused by the in vivo redistribution of 134La. However, this same characteristic makes it possible to estimate the redistribution of 225Ac's progeny noninvasively. In future studies, this unique PET in vivo generator will further be harnessed to study tracer internalization, trafficking of receptors, and the progression of the tumour microenvironment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

Author

Kramer, Kim, Pandit-Taskar, Neeta, Kushner, Brian H., Zanzonico, Pat, Humm, John L., Tomlinson, Ursula, Donzelli, Maria, Wolden, Suzanne L., Haque, Sophia, Dunkel, Ira, Souweidane, Mark M., Greenfield, Jeffrey P., Tickoo, Satish, Lewis, Jason S., Lyashchenko, Serge K., Carrasquillo, Jorge A., Chu, Bae, Horan, Christopher, Larson, Steven M., Cheung, Nai-Kong V., and Modak, Shakeel

Published
2022
Full Text
View/download PDF

25. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer

Author

Imberti, Cinzia, primary, De Gregorio, Roberto, additional, Korsen, Joshua A., additional, Hoang, Tran T., additional, Khitrov, Samantha, additional, Kalidindi, Teja, additional, Nandakumar, Subhiksha, additional, Park, Jooyoung, additional, Zaidi, Samir, additional, Pillarsetty, Naga Vara Kishore, additional, and Lewis, Jason S., additional

Published
2024
Full Text
View/download PDF

29. First-in-Human Evaluation of Site-Specifically Labeled89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer

Author

Yeh, Randy, primary, O’Donoghue, Joseph A., additional, Jayaprakasam, Vetri Sudar, additional, Mauguen, Audrey, additional, Min, Ryan, additional, Park, Sue, additional, Brockway, Julia P., additional, Bromberg, Jacqueline F., additional, Zhi, W Iris, additional, Robson, Mark E., additional, Sanford, Rachel, additional, Modi, Shanu, additional, Agnew, Brian J., additional, Lyashchenko, Serge K., additional, Lewis, Jason S., additional, Ulaner, Gary A., additional, and Zeglis, Brian M., additional

Published
2024
Full Text
View/download PDF

30. Correction to “Shifting the Antibody–Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy against Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Mouse Model”

Author

Ahad, Afruja, primary, Saeed, Hiwa K., additional, del Solar, Virginia, additional, López-Hernández, Javier E., additional, Michel, Alexa, additional, Mathew, Joshua, additional, Lewis, Jason S., additional, and Contel, Maria, additional

Published
2024
Full Text
View/download PDF

33. 212Pb-Pretargeted Theranostics for Pancreatic Cancer

Author

Bauer, David, primary, Carter, Lukas M., additional, Atmane, Mohamed I., additional, De Gregorio, Roberto, additional, Michel, Alexa, additional, Kaminsky, Spencer, additional, Monette, Sebastien, additional, Li, Mengshi, additional, Schultz, Michael K., additional, and Lewis, Jason S., additional

Published
2023
Full Text
View/download PDF

34. Supplementary Table S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Methods S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure S10 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

38. Data from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, primary, Walch, Henry, primary, Chou, Joanne F., primary, Ceglia, Nicholas, primary, Ptashkin, Ryan, primary, Do, Richard Kinh Gian, primary, Paroder, Viktoriya, primary, Pandit-Taskar, Neeta, primary, Lewis, Jason S., primary, Biachi De Castria, Tiago, primary, Sabwa, Shalom, primary, Socolow, Fiona, primary, Feder, Lara, primary, Thomas, Jasmine, primary, Schulze, Isabell, primary, Kim, Kwanghee, primary, Elzein, Arijh, primary, Bojilova, Viktoria, primary, Zatzman, Matthew, primary, Bhanot, Umesh, primary, Nagy, Rebecca J., primary, Lee, Jeeyun, primary, Simmons, Marc, primary, Segal, Michal, primary, Ku, Geoffrey Yuyat, primary, Ilson, David H., primary, Capanu, Marinela, primary, Hechtman, Jaclyn F., primary, Merghoub, Taha, primary, Shah, Sohrab, primary, Schultz, Nikolaus, primary, Solit, David B., primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

40. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Author

Maron, Steven B., primary, Chatila, Walid, additional, Walch, Henry, additional, Chou, Joanne F., additional, Ceglia, Nicholas, additional, Ptashkin, Ryan, additional, Do, Richard Kinh Gian, additional, Paroder, Viktoriya, additional, Pandit-Taskar, Neeta, additional, Lewis, Jason S., additional, Biachi De Castria, Tiago, additional, Sabwa, Shalom, additional, Socolow, Fiona, additional, Feder, Lara, additional, Thomas, Jasmine, additional, Schulze, Isabell, additional, Kim, Kwanghee, additional, Elzein, Arijh, additional, Bojilova, Viktoria, additional, Zatzman, Matthew, additional, Bhanot, Umesh, additional, Nagy, Rebecca J., additional, Lee, Jeeyun, additional, Simmons, Marc, additional, Segal, Michal, additional, Ku, Geoffrey Yuyat, additional, Ilson, David H., additional, Capanu, Marinela, additional, Hechtman, Jaclyn F., additional, Merghoub, Taha, additional, Shah, Sohrab, additional, Schultz, Nikolaus, additional, Solit, David B., additional, and Janjigian, Yelena Y., additional

Published
2023
Full Text
View/download PDF

43. Development and Validation of Nerve-Targeted Bacteriochlorin Sensors

Author

Hernández-Gil, Javier, Chow, Chun Yuen, Chatras; Hugo, de Souza França, Paula Demétrio, Samuels, Zachary V., Cornejo, Mike, King, Glenn F., Lewis, Jason S., Reiner, Thomas, Gonzales, Junior, Hernández-Gil, Javier, Chow, Chun Yuen, Chatras; Hugo, de Souza França, Paula Demétrio, Samuels, Zachary V., Cornejo, Mike, King, Glenn F., Lewis, Jason S., Reiner, Thomas, and Gonzales, Junior

Abstract

We report an innovative approach to producing bacteriochlorins (bacs) via formal cycloaddition by subjecting a porphyrin to a trimolecular reaction. Bacs are near-infrared probes with the intrinsic ability to serve in multimodal imaging. However, despite their ability to fluoresce and chelate metal ions, existing bacs have thus offered limited ability to label biomolecules for target specificity or have lacked chemical purity, limiting their use in bio-imaging. In this work, bacs allowed a precise and controlled appending of clickable linkers, lending the porphyrinoids substantially more chemical stability, clickability, and solubility, rendering them more suitable for preclinical investigation. Our bac probes enable the targeted use of biomolecules in fluorescence imaging and Cerenkov luminescence for guided intraoperative imaging. Bacs’ capacity for chelation provides opportunities for use in non-invasive positron emission tomography/computed tomography. Herein, we report the labeling of bacs with Hs1a, a (NaV1.7)-sodium-channel-binding peptide derived from the Chinese tarantula Cyriopagopus schmidti to yield Bac-Hs1a and radiolabeled Hs1a, which shuttles our bac sensor(s) to mouse nerves. In vivo, the bac sensor allowed us to observe high signal-to-background ratios in the nerves of animals injected with fluorescent Bac-Hs1a and radiolabeled Hs1a in all imaging modes. This study demonstrates that Bac-Hs1a and [Cu]Cu-Bac-Hs1a accumulate in peripheral nerves, providing contrast and utility in the preclinical space. For the chemistry and bio-imaging fields, this study represents an exciting starting point for the modular manipulation of bacs, their development and use as probes for diagnosis, and their deployment as formidable multiplex nerve-imaging agents for use in routine imaging experiments.

Published
2023

50. Data from EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

Author

Sanchez-Vega, Francisco, primary, Hechtman, Jaclyn F., primary, Castel, Pau, primary, Ku, Geoffrey Y., primary, Tuvy, Yaelle, primary, Won, Helen, primary, Fong, Christopher J., primary, Bouvier, Nancy, primary, Nanjangud, Gouri J., primary, Soong, Joanne, primary, Vakiani, Efsevia, primary, Schattner, Mark, primary, Kelsen, David P., primary, Lefkowitz, Robert A., primary, Brown, Karen, primary, Lacouture, Mario E., primary, Capanu, Marinela, primary, Mattar, Marissa, primary, Qeriqi, Besnik, primary, Cecchi, Fabiola, primary, Tian, Yuan, primary, Hembrough, Todd, primary, Nagy, Rebecca J., primary, Lanman, Richard B., primary, Larson, Steven M., primary, Pandit-Taskar, Neeta, primary, Schöder, Heiko, primary, Iacobuzio-Donahue, Christine A., primary, Ilson, David H., primary, Weber, Wolfgang A., primary, Berger, Michael F., primary, de Stanchina, Elisa, primary, Taylor, Barry S., primary, Lewis, Jason S., primary, Solit, David B., primary, Carrasquillo, Jorge A., primary, Scaltriti, Maurizio, primary, Schultz, Nikolaus, primary, and Janjigian, Yelena Y., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results